Resources

Ablexis’ multi-target licensing agreement grants Almirall rights to use the AlivaMab® Mouse technology for research, development and commercialization of antibodies ...
CONTINUE READING

AbbVie veteran to support rapid growth and new technologies. SAN DIEGO, Calif. – January 11, 2022 – AlivaMab Discovery Services (“ADS”), a ...
CONTINUE READING

Expanded agreement aims to accelerate the discovery of next-generation antibody modalities SAN DIEGO, Calif. – November 1, 2021 – AlivaMab Discovery ...
CONTINUE READING

Agreement aims to accelerate the discovery of new therapeutics SAN DIEGO, Calif. – September 14, 2021 – AlivaMab Discovery Services (“ADS”), a ...
CONTINUE READING

Expansion gives AlivaMab Discovery Services the ability to streamline the transition of drug discovery programs into development SAN DIEGO, Calif ...
CONTINUE READING

ADS announces integrated antibody drug discovery collaboration SAN DIEGO, Calif. – June 3, 2020 – AlivaMab Discovery Services, LLC, a ...
CONTINUE READING

Offers unique resources for COVID-19 therapeutic discovery SAN DIEGO and EMERYVILLE, Calif. – April 22, 2020 – Ablexis, LLC, AlivaMab ...
CONTINUE READING

ADS to provide expertise and capabilities in antibody drug discovery  SAN DIEGO, Calif. –  September 16, 2019 – AlivaMab Discovery ...
CONTINUE READING

Company Expands Team with Veterans of Antibody Discovery and Development   SAN DIEGO, Calif. – February 26, 2019 – AlivaMab ...
CONTINUE READING